Argos Therapeutics (NASDAQ: ARGS) is one of 50 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its peers? We will compare Argos Therapeutics to similar businesses based on the strength of its institutional ownership, profitability, analyst recommendations, valuation, dividends, earnings and risk.

Institutional and Insider Ownership

27.9% of Argos Therapeutics shares are owned by institutional investors. Comparatively, 44.9% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 28.2% of Argos Therapeutics shares are owned by company insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


This table compares Argos Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Argos Therapeutics -12,391.15% -1,532.49% -92.03%
Argos Therapeutics Competitors -13,462.32% -176.39% -24.75%

Volatility & Risk

Argos Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Argos Therapeutics’ peers have a beta of 1.18, indicating that their average share price is 18% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Argos Therapeutics and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Argos Therapeutics 0 3 0 0 2.00
Argos Therapeutics Competitors 129 800 1742 59 2.63

Argos Therapeutics presently has a consensus target price of $4.13, indicating a potential upside of 2,331.37%. As a group, “Biopharmaceuticals” companies have a potential upside of 12.48%. Given Argos Therapeutics’ higher possible upside, equities analysts plainly believe Argos Therapeutics is more favorable than its peers.

Valuation and Earnings

This table compares Argos Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Argos Therapeutics $950,000.00 -$53.02 million -0.13
Argos Therapeutics Competitors $585.03 million $106.82 million 56.92

Argos Therapeutics’ peers have higher revenue and earnings than Argos Therapeutics. Argos Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


Argos Therapeutics peers beat Argos Therapeutics on 8 of the 12 factors compared.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.